Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
about
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Current achievements and future perspectives of metronomic chemotherapy.Therapy-activated stromal cells can dictate tumor fate.Resistance to metronomic chemotherapy and ways to overcome it.Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer.Contralateral breast cancers: Independent cancers or metastases?Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients
P2860
Q37160109-04D13759-CDAE-4465-8BC1-2751BAE2760EQ37709874-0171126B-10F5-4E6A-A811-1F9DCD867F22Q38697494-F3F5A3BA-DF05-4EC9-970F-3299CD981419Q38722809-752E2E29-E806-4321-A6AF-C965EE7760D7Q38788234-F807928C-45BD-4697-AD20-DFC94C79BECBQ39018465-E458D4E7-4A50-463E-9241-AA7468E3A7F9Q40448516-F3FC2258-D707-44C8-8BA2-835175048B28Q46165703-1E30F4F0-BC53-42A9-99D2-C6452C50EF7CQ47103586-6DF8BD34-BC6B-4F9A-B3CB-4990BD7D4027Q47149222-7433DA39-4D17-4980-9BCB-F107AB33BCB2Q47683672-2374D38E-CC4C-47EB-BCFE-D95D3711CFC3Q47732726-AC4406BB-498E-4A64-B7D3-8977903D2286Q47988029-6D83AAC9-DC34-41F8-A58B-56560774FF69Q52755645-3660095B-A04A-4A27-A0AC-43266EDBDDCFQ55383509-9BEF2273-D5C7-435C-89C7-9B2A8DCE333EQ57495758-A030307C-B921-47F3-AE67-26B0939FFC46
P2860
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@ast
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@en
type
label
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@ast
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@en
prefLabel
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@ast
Low-Dose Oral Cyclophosphamide ...... ancer Study Group Trial 22-00.
@en
P2093
P2860
P50
P356
P1476
Low-Dose Oral Cyclophosphamide ...... Cancer Study Group Trial 22-00
@en
P2093
Alan S Coates
Alexandru Eniu
Aron Goldhirsch
Barbro K Linderholm
Beat Thürlimann
Carlo Tondini
Daniel Rauch
Ehtesham A Abdi
Elena Kralidis
Giuseppe Viale
P2860
P304
P356
10.1200/JCO.2015.65.6595
P407
P577
2016-06-20T00:00:00Z